Advertisement
Advertisement
NVAX
Novavax Inc
10.62
USDSponsored
-0.04
-0.33%
Nov 05, 09:41 UTC -5
Open
Novavax Inc (NVAX) Earnings
NVAX Earnings Reports
Positive Surprise Ratio
NVAX beat 21 of 44 last estimates.
48%
Next Report
Date of Next Report
Feb 24, 2027
Estimate for Q4 26 (Revenue/ EPS)
$125.67M
/$0.00
Implied change from Q3 26 (Revenue/ EPS)
+84.00%
/-100.00%
Implied change from Q4 25 (Revenue/ EPS)
-14.59%
/-100.00%
Novavax Inc earnings per share and revenue
On Nov 05, 2026, NVAX reported earnings of -0.19 USD per share (EPS) for Q3 26, beating the estimate of -0.34 USD, resulting in a 44.56% surprise. Revenue reached 68.30 million, compared to an expected 51.44 million, with a 32.78% difference.
Looking ahead to Q4 26, 7 analysts forecast an EPS of 0.00 USD, with revenue projected to reach 125.67 million USD, implying an decrease of -100.00% EPS, and increase of 84.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Agios Pharmaceuticals, Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$1.24
Actual
-$1.09
Surprise
+12.58%
Intellia Therapeutics, Inc
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.81
Actual
-$0.91
Surprise
-11.97%
Certara, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.09
Actual
$0.09
Surprise
-0.88%
ANI Pharmaceuticals, Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
$2.22
Actual
$2.70
Surprise
+21.37%
Lexicon Pharmaceuticals, Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.05
Actual
-$0.03
Surprise
+49.41%
SAB Biotherapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.24
Surprise
+12.85%
Cognition Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.06
Actual
-$0.04
Surprise
+41.18%
Iovance Biotherapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.05
Surprise
+42.59%
Disc Medicine, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$1.76
Actual
-$1.53
Surprise
+13.11%
Palvella Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$1.82
Actual
-$1.70
Surprise
+7.05%
FAQ
What were Novavax Inc's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Novavax Inc reported EPS of -$0.19, beating estimates by 44.56%, and revenue of $68.30M, 32.78% above expectations.
How did the market react to Novavax Inc's Q3 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Novavax Inc expected to report next?
The next earning report is scheduled for Feb 24, 2027.
What are the forecasts for Novavax Inc's next earnings report?
Based on 7
analysts, Novavax Inc is expected to report EPS of -- and revenue of $125.67M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.